ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO444

Effect of Cytokine Adsorption on Mortality: A Meta-Analysis

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Schmidt, Bernhard M.W., Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
  • Lang, Hannah, Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
  • Vollmer Barbosa, Clara, Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
  • Tian, Zhejia, Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
  • Melk, Anette, 2Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Hannover, Germany
Background

Cytokine adsorption using the CytoSorb® device had been proposed to be beneficial in various clinical settings including sepsis, ARDS, hyperinflammatory syndromes, cardiac surgery or recovery after cardiac arrest. The aim of this analysis was to provide evidence for the efficacy of the CytoSorb® device with regard to mortality in these settings.

Methods

We searched Medline, Cochrane Library database and used the database provided by CytosorbentsTM. Central Register of Controlled Trials and clinicaltrials.gov for randomized, controlled studies (01.1.2010-28.2.22). We considered randomized controlled trials and observational studies with a control group. The longest reported mortality (30 days-, hospital- or ICU-mortality) was defined as primary endpoint. For analyzing the data we computed risk ratios and 95%-confidence intervals and used DerSimonian and Lairds random effects model (R 4.1). We analysed all studies together and separated in the subgroups sepsis, cardiac surgery, SARS-CoV-2 infection, recovery from cardiac arrest, other severe illness. The meta-analysis was registered in advance (PROSPERO: CRD42022290334).

Results

Of initial 1249 publications, 37 trials were found eligible, in total including 1256 patients treated with CytoSorb® and 1230 controls. Concerning the primary endpoint mortality Cytosorb® did not show a positive effect in all studies together 1.10 [0.92; 1.33] RR [95%-CI], in sepsis 1.03 [0.81; 1.31], CPB surgery 0.85 [0.51; 1.44], severe illness 1.05 [0.79; 1.39], SARS-CoV-2 1.58 [0.50; 4.94], and recovery from cardiac arrest 1.22 [1.02; 1.46] (figure). Likewise we did not find significant difference in ICU length of stay, lactate levels, or norepinephrine after treatment.

Conclusion

To date there is no evidence for a positive effect of the CytoSorb® adsorber on mortality across a bunch of indications that justifies its widespread use in intensive care medicine.